Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab

Abstract Novel predictive biomarkers are needed to improve patient selection and optimize the use of bevacizumab (B) in metastatic colorectal cancer. We analyzed the potential of five circulating biomarkers to predict B efficacy and monitor response. Peripheral blood samples collected at baseline, a...

Full description

Bibliographic Details
Main Authors:	Giorgia Marisi, Emanuela Scarpi, Alessandro Passardi, Oriana Nanni, Angela Ragazzini, Martina Valgiusti, Andrea Casadei Gardini, Luca Maria Neri, Giovanni Luca Frassineti, Dino Amadori, Paola Ulivi
Format:	Article
Language:	English
Published:	Nature Portfolio 2017-05-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-017-01420-0

Similar Items

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
by: Marisi G, et al.
Published: (2018-11-01)

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
by: Paola Ulivi, et al.
Published: (2018-01-01)

Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer
by: Giorgia Marisi, et al.
Published: (2023-08-01)

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
by: Ulivi Paola, et al.
Published: (2012-05-01)

Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial
by: Elisabetta Petracci, et al.
Published: (2020-07-01)

Prognostic Role of a New Inflammatory Index with Neutrophil-to-Lymphocyte Ratio and Lactate Dehydrogenase (CII: Colon Inflammatory Index) in Patients with Metastatic Colorectal Cancer: Results from the Randomized Italian Trial in Advanced Colorectal Cancer (ITACa) Study [Corrigendum]
by: Casadei-Gardini A, et al.
Published: (2020-01-01)

Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study
by: Casadei-Gardini A, et al.
Published: (2019-05-01)

Erratum: Passardi, A. et al. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. <i>Cancers</i> 2019, <i>11</i>, 663
by: Alessandro Passardi, et al.
Published: (2020-01-01)

Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study
by: Alessandro Passardi, et al.
Published: (2019-05-01)

Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab
by: Alessandro Passardi, et al.
Published: (2023-12-01)

Metastatic Colorectal Cancer
by: Alessandro Passardi, et al.
Published: (2021-12-01)

Towards Personalized Treatment and Molecular Research on Gastrointestinal Tumors
by: Alessandro Passardi, et al.
Published: (2023-09-01)

Special Issue on Molecular and Translational Research on Colorectal Cancer 2.0
by: Alessandro Passardi, et al.
Published: (2021-07-01)

Molecular and Translational Research on Colorectal Cancer
by: Alessandro Passardi, et al.
Published: (2020-06-01)

Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis
by: Ilario Giovanni Rapposelli, et al.
Published: (2021-01-01)

Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients
by: Francesca Pirini, et al.
Published: (2020-05-01)

Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience
by: Maltoni Roberta, et al.
Published: (2006-03-01)

<i>ANGPT2</i> and <i>NOS3</i> Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
by: Giorgia Marisi, et al.
Published: (2019-07-01)

Recent Research on Gastrointestinal Carcinoma
by: Giulia Rovesti, et al.
Published: (2021-01-01)

Development and Validation of the PaP Score Nomogram for Terminally Ill Cancer Patients
by: Emanuela Scarpi, et al.
Published: (2022-05-01)

Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies
by: Alessandro Passardi, et al.
Published: (2021-08-01)

Neoadjuvant treatment (FOLFOX4 plus hypofractionated tomotherapy) for patients with locally advanced rectal cancer: a multicenter phase II trial
by: Alessandro Passardi, et al.
Published: (2020-12-01)

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
by: Zoli Wainer, et al.
Published: (2008-10-01)

<sup>1</sup>H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages
by: Andrea Casadei-Gardini, et al.
Published: (2020-01-01)

Multiple marker detection in peripheral blood for NSCLC diagnosis.
by: Paola Ulivi, et al.
Published: (2013-01-01)

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
by: Ilario Giovanni Rapposelli, et al.
Published: (2021-05-01)

Mathematical Model Predicts Effective Strategies to Inhibit VEGF-eNOS Signaling
by: Qianhui Wu, et al.
Published: (2020-04-01)

Does anti-VEGF bevacizumab improve survival in experimental sepsis?
by: Emmanuel Besnier, et al.
Published: (2017-07-01)

Computer Simulation of TSP1 Inhibition of VEGF–Akt–eNOS: An Angiogenesis Triple Threat
by: Hojjat Bazzazi, et al.
Published: (2018-05-01)

Podocyte VEGF-A Knockdown Induces Diffuse Glomerulosclerosis in Diabetic and in eNOS Knockout Mice
by: Delma Veron, et al.
Published: (2022-02-01)

Telomerase Activity Detected by Quantitative Assay in Bladder Carcinoma and Exfoliated Cells in Urine
by: Roberta Fedriga, et al.
Published: (2001-01-01)

Blocking VEGF by Bevacizumab Compromises Electrophysiological and Morphological Properties of Hippocampal Neurons
by: Pauline Latzer, et al.
Published: (2019-03-01)

Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study
by: Leonardo Solaini, et al.
Published: (2019-03-01)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
by: Laura Marconato, et al.
Published: (2020-05-01)

Differential roles of eNOS in late effects of VEGF-A on hyperpermeability in different types of endothelial cells
by: Esmeralda K. Bosma, et al.
Published: (2023-12-01)

EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model?
by: Rossella Terragni, et al.
Published: (2014-01-01)

VEGF and eNOS genes polymorphism features in patients with diabetes mellitus with and without initial non-proliferative diabetic retinopathy
by: A. V. Shevchenko, et al.
Published: (2021-12-01)

An Integrated Model to Improve Medication Reconciliation in Oncology: Prospective Interventional Study
by: Alessandro Passardi, et al.
Published: (2021-12-01)

Sympathetic activation increases NO release from eNOS but neither eNOS nor nNOS play an essential role in exercise hyperemia in the human forearm.
by: Shabeeh, H, et al.
Published: (2013)

VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.
by: Varey, A, et al.
Published: (2008)